Knecht Sébastien, Sacher Frédéric, Wright Matthew, Hocini Mélèze, Nogami Akihiko, Arentz Thomas, Petit Bertrand, Franck Robert, De Chillou Christian, Lamaison Dominique, Farré Jéronimo, Lavergne Thomas, Verbeet Thierry, Nault Isabelle, Matsuo Seiichiro, Leroux Lionel, Weerasooriya Rukshen, Cauchemez Bruno, Lellouche Nicolas, Derval Nicolas, Narayan Sanjiv M, Jaïs Pierre, Clementy Jacques, Haïssaguerre Michel
Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France.
J Am Coll Cardiol. 2009 Aug 4;54(6):522-8. doi: 10.1016/j.jacc.2009.03.065.
This multicenter study sought to evaluate the long-term follow-up of patients ablated for idiopathic ventricular fibrillation (VF).
Catheter ablation of idiopathic VF that targets ventricular premature beat (VPB) triggers has been shown to prevent VF recurrences on short-term follow-up.
From January 2000, 38 consecutive patients from 6 different centers underwent ablation of primary idiopathic VF initiated by short coupled VPB. All patients had experienced at least 1 documented VF, with 87% having experienced > or =2 VF episodes in the preceding year. Catheter ablation was guided by activation mapping of VPBs or pace mapping during sinus rhythm.
There were 38 patients (21 men) age 42 +/- 13 years, refractory to a median of 2 antiarrhythmic drugs. Triggering VPBs originated from the right (n = 16), the left (n = 14), or both (n = 3) Purkinje systems and from the myocardium (n = 5). During a median post-procedural follow-up of 63 months, 7 (18%) of 38 patients experienced VF recurrence at a median of 4 months. Five of these 7 patients underwent repeat ablation without VF recurrence. Survival free of VF was predicted only by transient bundle-branch block in the originating ventricle during the electrophysiological study (p < 0.0001). The number of significant events (confirmed VF or aborted sudden death) was reduced from 4 (interquartile range 3 to 9) before to 0 (interquartile range 0 to 4) after ablation (p = 0.01).
Ablation for idiopathic VF that targets short coupled VPB triggers is associated with a long-term freedom from VF recurrence.
本多中心研究旨在评估接受特发性室颤(VF)消融治疗患者的长期随访情况。
针对室性早搏(VPB)触发灶进行的特发性VF导管消融已被证明在短期随访中可预防VF复发。
从2000年1月起,来自6个不同中心的38例连续患者接受了由短联律VPB引发的原发性特发性VF消融治疗。所有患者均至少有1次记录在案的VF发作,其中87%的患者在前一年经历过≥2次VF发作。导管消融在窦性心律期间通过VPB的激动标测或起搏标测进行引导。
共有38例患者(21例男性),年龄42±13岁,对中位数为2种抗心律失常药物耐药。触发VPB起源于右(n = 16)、左(n = 14)或双侧(n = 3)浦肯野系统以及心肌(n = 5)。在术后中位随访63个月期间,38例患者中有7例(18%)在中位4个月时经历了VF复发。这7例患者中有5例接受了再次消融,未再发生VF复发。仅通过电生理研究期间起源心室的短暂束支阻滞可预测无VF生存(p < 0.0001)。消融前显著事件(确诊VF或未遂心源性猝死)的数量从4次(四分位间距3至9次)降至消融后0次(四分位间距0至4次)(p = 0.01)。
针对短联律VPB触发灶进行的特发性VF消融与长期无VF复发相关。